Is Final Dose profitable in 2026?

No. As of July 25, 2026, Final Dose is a pre-clinical, stealth-stage biotech with no revenue, no customers, and no marketed product. Its entire value proposition rests on an unproven claim that a single molecule can recognize and kill cancer cells by DNA sequence.

Could AI replace what Final Dose is building?

Not the core therapy. AI commoditizes upstream target discovery and CRISPR screening (its founders already used ML coevolution to cut validation from months to days), but the regulated molecule itself, clinical trials, and IP approval are not AI-replaceable, per the company's May 2026 framing.

Who is Final Dose's biggest competitor?

CRISPR Therapeutics, with clinical-stage allogeneic CAR-T programs CTX110 and CTX120, sits closest structurally. Academically, a June 2026 Nature paper on RNA-triggered chromatin shredding targets the same cancer-specific-mutation space, unaffiliated with Final Dose but attacking the same open room.

Final Dose is privately held and backed by Y Combinator as part of its P26/X26 batch. No dedicated funding round, investor list, or valuation for Final Dose itself has been publicly disclosed as of July 25, 2026.

What does Final Dose actually claim its drug does?

Per its May 12, 2026 Launch YC posting, Final Dose describes a single reprogrammable molecule that recognizes diseased cells by DNA sequence and destroys them, initially targeting 'all cancers' and claiming to unlock 80 percent of currently undruggable targets.

Has Final Dose raised any funding?

No dedicated Final Dose funding round has been publicly disclosed as of July 2026. Figures like a $5M seed and $10M Pre-Series A belong to CEO Jeff Liu's prior company, Vivid Dx, not to Final Dose.

YC Spring 2026 · United Kingdom

Final Dose

finaldose.ai ↗

Stealth YC startup building one injectable drug meant to recognize and kill any cancer by DNA sequence.

Losing its protection

Assessed 27 July 2026 · Evidence as of 27 July 2026

The structural protection is eroding.

On the recordSince 27 July 2026 · Checkable from December 2026 · Every call on the record Checkpoint: Promised fuller public unveiling and first preclinical data disclosure

The call

Final Dose is a five-person, pre-clinical company betting on one unproven molecule to cure cancer, with no published data yet and rivals publishing similar science.

Final Dose is working on a single injectable drug designed to find and kill cancer cells by reading their DNA, supposedly working against all cancer types. The company's main challenge is that this idea has never been proven to work in actual patients, and other groups like CRISPR Therapeutics or academic labs could publish similar research at any time and claim the same territory. The one thing that matters most: does Final Dose show its science actually works in early lab tests before competitors beat them to it, or before AI tools help other companies discover the same approach faster.

Why

AI pressure: Frontier AI models (Claude, GPT-class systems) doing target discovery and CRISPR screening. AI tools speed up finding cancer targets for everyone, so Final Dose's head start on discovery could shrink fast. Could AI do the core job? Unlikely.

Bigger players: CRISPR Therapeutics, Beam, Prime, Intellia, and academic labs publishing similar gene-editing cancer work. A June 2026 Nature paper on RNA-triggered chromatin shredding shows outside groups chasing the same DNA-sequence-gated kill mechanism. Could a giant copy it? Yes, easily.

What protects it. No one has published or filed on this exact DNA-sequence-gated cytotoxic payload yet, so the room stays open only until someone else claims it.

What would change this call

Final Dose publishes in-vivo preclinical data showing tumor shrinkage with clean safety readout. Would show the core molecule claim has real proof-of-concept, not just theory.
A competing academic group or firm like CRISPR Therapeutics publishes a DNA-sequence-gated cytotoxic payload within 12 months. Would show the architecture window has closed and the room is no longer open.
Final Dose files an IND or discloses a Series A close and staff growth beyond 5 people. Would show the company is converting stealth-stage claims into funded, regulated progress.

Key numbers

5 employees, based in London (2026-07-25)
Still in stealth mode, no public data (2026-07-25)
Confirmed member of YC P26/X26 batch (2026-07-25)

Named risks

Core cytotoxic DNA-recognition mechanism has no published preclinical, IP, or trial data as of July 2026. Severity: high
Regulatory pathway for a novel programmable therapeutic modality is unresolved, flagged by CEO himself. Severity: high
Academic or incumbent groups could publish a matching DNA-sequence-gated payload architecture within 12 months, closing the open window. Severity: medium
5-person team is smaller than several similarly staged YC therapeutics peers, limiting execution capacity. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
CRISPR Therapeutics	contesting	Runs clinical-stage allogeneic CAR-T programs CTX110/CTX120, unlike Final Dose's pre-clinical stage
Academic groups (Nature, June 2026)	gaining on	Published RNA-triggered chromatin shredding for cancer-specific mutations, 2026-06-07
Kopra Bio (YC S2024)	contesting	Vendor-claimed preclinical survival gains for oncolytic viruses in glioblastoma, as of 2026-07-25
Granza Bio (YC W2024)	contesting	7 employees vs Final Dose's 5, building rival programmable immune-cell delivery platform, 2026-07-25

Questions people ask

Is Final Dose profitable in 2026?: No. As of July 25, 2026, Final Dose is a pre-clinical, stealth-stage biotech with no revenue, no customers, and no marketed product. Its entire value proposition rests on an unproven claim that a single molecule can recognize and kill cancer cells by DNA sequence.
Could AI replace what Final Dose is building?: Not the core therapy. AI commoditizes upstream target discovery and CRISPR screening (its founders already used ML coevolution to cut validation from months to days), but the regulated molecule itself, clinical trials, and IP approval are not AI-replaceable, per the company's May 2026 framing.
Who is Final Dose's biggest competitor?: CRISPR Therapeutics, with clinical-stage allogeneic CAR-T programs CTX110 and CTX120, sits closest structurally. Academically, a June 2026 Nature paper on RNA-triggered chromatin shredding targets the same cancer-specific-mutation space, unaffiliated with Final Dose but attacking the same open room.
Who owns Final Dose?: Final Dose is privately held and backed by Y Combinator as part of its P26/X26 batch. No dedicated funding round, investor list, or valuation for Final Dose itself has been publicly disclosed as of July 25, 2026.
What does Final Dose actually claim its drug does?: Per its May 12, 2026 Launch YC posting, Final Dose describes a single reprogrammable molecule that recognizes diseased cells by DNA sequence and destroys them, initially targeting 'all cancers' and claiming to unlock 80 percent of currently undruggable targets.
Has Final Dose raised any funding?: No dedicated Final Dose funding round has been publicly disclosed as of July 2026. Figures like a $5M seed and $10M Pre-Series A belong to CEO Jeff Liu's prior company, Vivid Dx, not to Final Dose.

Timeline

2026-07-25YC directory lists Final Dose at 5 employees, based in London
2026-07-11Prior YC directory snapshot also shows Final Dose with 5 employees
2026-06-07Unaffiliated Nature paper on RNA-triggered chromatin shredding targets same cancer-DNA space
2026-05-25CEO Jeff Liu discusses regulatory bottleneck for programmable therapeutics on START pod
2026-05-12Final Dose publicly launches via Y Combinator's Launch YC platform
2026-04-15Unaffiliated MDPI paper on CRISPR interference to inhibit oncogenes published

Revision history

27 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Trellis Surtr Defense Systems HeyClicky